Northern Trust’s Adicet Bio ACET Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $131K | Buy |
19,200
+5,133
| +36% | +$38.4K | ﹤0.01% | 4046 |
|
|
2025
Q4 | $118K | Buy |
14,067
+5,294
| +60% | +$58.5K | ﹤0.01% | 4103 |
|
|
2025
Q3 | $114K | Hold |
8,773
| – | – | ﹤0.01% | 4107 |
|
|
2025
Q2 | $85.6K | Hold |
8,773
| – | – | ﹤0.01% | 4141 |
|
|
2025
Q1 | $106K | Hold |
8,773
| – | – | ﹤0.01% | 4098 |
|
|
2024
Q4 | $135K | Buy |
8,773
+1,759
| +25% | +$33.2K | ﹤0.01% | 4096 |
|
|
2024
Q3 | $162K | Sell |
7,014
-18,145
| -72% | -$406K | ﹤0.01% | 3945 |
|
|
2024
Q2 | $487K | Sell |
25,159
-2,067
| -8% | -$55.4K | ﹤0.01% | 3523 |
|
|
2024
Q1 | $1.02M | Buy |
27,226
+12,721
| +88% | +$526K | ﹤0.01% | 3295 |
|
|
2023
Q4 | $439K | Buy |
14,505
+105
| +0.7% | +$2.29K | ﹤0.01% | 3578 |
|
|
2023
Q3 | $316K | Sell |
14,400
-725
| -5% | -$25.6K | ﹤0.01% | 3647 |
|
|
2023
Q2 | $588K | Sell |
15,125
-1,277
| -8% | -$113K | ﹤0.01% | 3500 |
|
|
2023
Q1 | $1.51M | Sell |
16,402
-252
| -2% | -$31.6K | ﹤0.01% | 3065 |
|
|
2022
Q4 | $2.38M | Buy |
16,654
+1,592
| +11% | +$397K | ﹤0.01% | 2903 |
|
|
2022
Q3 | $3.43M | Buy |
15,062
+1,077
| +8% | +$273K | ﹤0.01% | 2716 |
|
|
2022
Q2 | $3.27M | Buy |
13,985
+1,222
| +10% | +$268K | ﹤0.01% | 2784 |
|
|
2022
Q1 | $4.08M | Buy |
12,763
+2,166
| +20% | +$498K | ﹤0.01% | 2703 |
|
|
2021
Q4 | $2.96M | Sell |
10,597
-228
| -2% | -$39.1K | ﹤0.01% | 3013 |
|
|
2021
Q3 | $1.36M | Sell |
10,825
-621
| -5% | -$77K | ﹤0.01% | 3442 |
|
|
2021
Q2 | $1.89M | Buy |
11,446
+9,822
| +605% | +$2M | ﹤0.01% | 3373 |
|
|
2021
Q1 | $340K | Buy |
+1,624
| New | +$373K | ﹤0.01% | 3936 |
|
|
2020
Q3 | – | Sell |
-269
| Closed | -$65K | – | 4292 |
|
|
2020
Q2 | $65K | Sell |
269
-1,384
| -84% | -$272K | ﹤0.01% | 4006 |
|
|
2020
Q1 | $191K | Buy |
1,653
+86
| +5% | +$12.8K | ﹤0.01% | 3694 |
|
|
2019
Q4 | $262K | Buy |
1,567
+16
| +1% | +$8.1K | ﹤0.01% | 3709 |
|
|
2019
Q3 | $1.54M | Buy |
1,551
+586
| +61% | +$654K | ﹤0.01% | 3240 |
|
|
2019
Q2 | $1.1M | Buy |
965
+260
| +37% | +$236K | ﹤0.01% | 3327 |
|
|
2019
Q1 | $539K | Sell |
705
-5
| -0.7% | -$4.54K | ﹤0.01% | 3526 |
|
|
2018
Q4 | $685K | Sell |
710
-29
| -4% | -$38.2K | ﹤0.01% | 3473 |
|
|
2018
Q3 | $1.25M | Buy |
739
+159
| +27% | +$207K | ﹤0.01% | 3408 |
|
|
2018
Q2 | $594K | Sell |
580
-21
| -3% | -$22.6K | ﹤0.01% | 3563 |
|
|
2018
Q1 | $645K | Buy |
+601
| New | +$1.1M | ﹤0.01% | 3504 |
|
Other funds holding ACET
RCM
O
VCM
WP
PM
SCM
Northern Trust's ACET Position: Q1 2026 in Review
Northern Trust increased its Adicet Bio (ACET) stake by 36% in Q1 2026, buying an estimated $38.4K and bringing the position to 19,200 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #4046.
Northern Trust first reported a position in ACET in Q1 2018 and has held it in 31 quarters since. The position peaked at $4.08M in Q1 2022. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.
- Northern Trust held 19,200 shares of Adicet Bio worth $131K as of Q1 2026.
- Northern Trust bought 5,133 Adicet Bio shares in Q1 2026, an estimated $38.4K.
- Adicet Bio made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4046 holding.
- Northern Trust first reported a position in Adicet Bio in Q1 2018 and has held it in 31 quarters since.
- Northern Trust's Adicet Bio position peaked at $4.08M in Q1 2022.
- 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.